Camurus’ Interim Report Third Quarter 2022
“The third quarter was financially Camurus’ best quarter to date” Third quarter summary July - September · Total revenues amounted to SEK 241 (154) million, an increase of 57% (45% at CER[1]), whereof product sales were SEK 241 (152) million, an increase of 58% (47% at CER) · Operating result was SEK 41 (-6) million, an increase of SEK 48 million · Cash position at the end of the quarter was SEK 520 (426) million, an increase of SEK 93 million · Number of patients treated with Buvidal[®] at the end of the quarter estimated at 32,000 · Total number of Buvidal units